Probity Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.07M | Sell |
12,209
-79
| -0.6% | -$17K | 0.44% | 46 |
|
|
2026
Q1 | $2.67M | Sell |
12,288
-224
| -2% | -$49.7K | 0.42% | 47 |
|
|
2025
Q4 | $2.86M | Sell |
12,512
-567
| -4% | -$129K | 0.46% | 42 |
|
|
2025
Q3 | $3.03M | Sell |
13,079
-297
| -2% | -$60.5K | 0.49% | 44 |
|
|
2025
Q2 | $2.48M | Sell |
13,376
-50
| -0.4% | -$9.29K | 0.44% | 47 |
|
|
2025
Q1 | $2.81M | Sell |
13,426
-60
| -0.4% | -$11.7K | 0.54% | 40 |
|
|
2024
Q4 | $2.4M | Sell |
13,486
-409
| -3% | -$75.2K | 0.46% | 47 |
|
|
2024
Q3 | $2.74M | Sell |
13,895
-288
| -2% | -$53.8K | 0.53% | 41 |
|
|
2024
Q2 | $2.43M | Sell |
14,183
-549
| -4% | -$90.9K | 0.5% | 44 |
|
|
2024
Q1 | $2.68M | Sell |
14,732
-541
| -4% | -$93.2K | 0.55% | 41 |
|
|
2023
Q4 | $2.37M | Sell |
15,273
-326
| -2% | -$47.5K | 0.52% | 36 |
|
|
2023
Q3 | $2.33M | Buy |
15,599
+117
| +0.8% | +$17.2K | 0.54% | 34 |
|
|
2023
Q2 | $2.09M | Buy |
+15,482
| New | +$2.27M | 0.46% | 36 |
|
|
2022
Q4 | $2.5M | Sell |
15,498
-539
| -3% | -$82.6K | 0.57% | 29 |
|
|
2022
Q3 | $2.15M | Sell |
16,037
-1,781
| -10% | -$256K | 0.53% | 29 |
|
|
2022
Q2 | $2.73M | Sell |
17,818
-567
| -3% | -$86.6K | 0.63% | 26 |
|
|
2022
Q1 | $2.98M | Sell |
18,385
-1,940
| -10% | -$282K | 0.61% | 27 |
|
|
2021
Q4 | $2.75M | Sell |
20,325
-374
| -2% | -$44.2K | 0.54% | 32 |
|
|
2021
Q3 | $2.23M | Sell |
20,699
-758
| -4% | -$86.6K | 0.46% | 40 |
|
|
2021
Q2 | $2.42M | Sell |
21,457
-270
| -1% | -$30.4K | 0.51% | 37 |
|
|
2021
Q1 | $2.35M | Buy |
+21,727
| New | +$2.32M | 0.53% | 36 |
|
|
2020
Q3 | $1.88M | Sell |
21,464
-153
| -0.7% | -$14.4K | 0.53% | 42 |
|
|
2020
Q2 | $2.12M | Buy |
21,617
+605
| +3% | +$53.3K | 0.66% | 32 |
|
|
2020
Q1 | $1.6M | Sell |
21,012
-129
| -0.6% | -$11K | 0.59% | 35 |
|
|
2019
Q4 | $1.87M | Sell |
21,141
-1,207
| -5% | -$100K | 0.57% | 39 |
|
|
2019
Q3 | $1.69M | Buy |
22,348
+32
| +0.1% | +$2.19K | 0.55% | 40 |
|
|
2019
Q2 | $1.62M | Sell |
22,316
-346
| -2% | -$27.2K | 0.54% | 42 |
|
|
2019
Q1 | $1.83M | Buy |
22,662
+662
| +3% | +$54.2K | 0.63% | 40 |
|
|
2018
Q4 | $2.03M | Sell |
22,000
-347
| -2% | -$30.5K | 0.75% | 33 |
|
|
2018
Q3 | $2.11M | Sell |
22,347
-277
| -1% | -$26.3K | 0.69% | 36 |
|
|
2018
Q2 | $2.1M | Buy |
22,624
+166
| +0.7% | +$16.2K | 0.74% | 32 |
|
|
2018
Q1 | $2.13M | Sell |
22,458
-1,191
| -5% | -$131K | 0.74% | 33 |
|
|
2017
Q4 | $2.29M | Sell |
23,649
-1,146
| -5% | -$108K | 0.8% | 28 |
|
|
2017
Q3 | $2.2M | Sell |
24,795
-293
| -1% | -$22.3K | 0.82% | 26 |
|
|
2017
Q2 | $1.82M | Sell |
25,088
-328
| -1% | -$22.1K | 0.69% | 29 |
|
|
2017
Q1 | $1.66M | Buy |
25,416
+3,214
| +14% | +$202K | 0.64% | 35 |
|
|
2016
Q4 | $1.39M | Buy |
22,202
+169
| +0.8% | +$10.3K | 0.58% | 38 |
|
|
2016
Q3 | $1.39M | Sell |
22,033
-97
| -0.4% | -$6.28K | 0.6% | 35 |
|
|
2016
Q2 | $1.37M | Buy |
+22,130
| New | +$1.35M | 0.61% | 35 |
|
Other funds holding ABBV
Probity Advisors's ABBV Position: Q2 2026 in Review
Probity Advisors reduced its AbbVie (ABBV) stake by 0.64% in Q2 2026, selling an estimated $17K and leaving 12,209 shares worth $3.07M. The position accounts for 0.44% of the portfolio, ranked #46.
Probity Advisors first reported a position in ABBV in Q2 2016 and has held it in 39 quarters since. 2,236 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Probity Advisors held 12,209 shares of AbbVie worth $3.07M as of Q2 2026.
- Probity Advisors sold 79 AbbVie shares in Q2 2026, an estimated $17K.
- AbbVie made up 0.44% of Probity Advisors's portfolio in Q2 2026, its #46 holding.
- Probity Advisors first reported a position in AbbVie in Q2 2016 and has held it in 39 quarters since.
- 2,236 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Probity Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.